{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:22:01Z","timestamp":1791836521746,"version":"4.3.4"},"reference-count":98,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>The current treatment of chronic HBV infection, pegylated interferon-\u03b1 (pegIFN\u03b1) and nucleos(t)ide analog (NA), can suppress HBV replication, reverse liver inflammation and fibrosis and reduce the risks of cirrhosis, HCC, and HBV-related deaths, but relapse is common when the treatment is stopped before HBsAg loss. There have been major efforts to develop a cure for HBV, defined as sustained HBsAg loss after a finite course of therapy. This requires the suppression of HBV replication and viral protein production and the restoration of immune response to HBV. Direct-acting antivirals targeting virus entry, capsid assembly, viral protein production and secretion are in clinical trials. Immune modulatory therapies to stimulate adaptive or innate immunity and\/or to remove immune blockade are being tested. NAs are included in most and pegIFN\u03b1 in some regimens. Despite the combination of 2 or more therapies, HBsAg loss remains rare in part because HbsAg can be derived not only from the covalently closed circular DNA but also from the integrated HBV DNA. Achievement of a functional HBV cure will require therapies to eliminate or silence covalently closed circular DNA and integrated HBV DNA. In addition, assays to differentiate the source of circulating HBsAg and to determine HBV immune recovery, as well as standardization and improvement of assays for HBV RNA and hepatitis B core-related antigen, surrogate markers for covalently closed circular DNA transcription, are needed to accurately assess response and to target treatments according to patient\/disease characteristics. Platform trials will allow the comparison of multiple combinations and channel patients with different characteristics to the treatment that is most likely to succeed. Safety is paramount, given the excellent safety profile of NA therapy.<\/jats:p>","DOI":"10.1097\/hc9.0000000000000084","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T19:00:34Z","timestamp":1679943634000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":36,"title":["What will it take to cure hepatitis B?"],"prefix":"10.1097","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-1259","authenticated-orcid":false,"given":"Wen-Juei","family":"Jeng","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5811-6845","authenticated-orcid":false,"given":"Anna S.F.","family":"Lok","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4]]},"reference":[{"key":"R2-20240826","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1281","article-title":"Treatment: what we know now and what remains to be researched","volume":"3","author":"Suk-Fong Lok","year":"2019","journal-title":"Hepatol Commun"},{"key":"R3-20240826","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"R4-20240826","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/liv.14851","article-title":"HBV 2021: new therapeutic strategies against an old foe","volume":"41","author":"Roca Suarez","year":"2021","journal-title":"Liver Int"},{"key":"R5-20240826","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-022-00724-5","article-title":"The scientific basis of combination therapy for chronic hepatitis B functional cure","author":"Lim","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatology"},{"key":"R6-20240826","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jhep.2018.08.012","article-title":"Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels","volume":"69","author":"Ko","year":"2018","journal-title":"J Hepatol"},{"key":"R7-20240826","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","article-title":"Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients","volume":"65","author":"Boyd","year":"2016","journal-title":"J Hepatol"},{"key":"R8-20240826","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.31240","article-title":"Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients","volume":"73","author":"Huang","year":"2021","journal-title":"Hepatology"},{"key":"R9-20240826","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/jvh.12434","article-title":"Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate","volume":"22","author":"Papatheodoridis","year":"2015","journal-title":"J Viral Hepat"},{"key":"R10-20240826","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jgh.12476","article-title":"Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment","volume":"29","author":"Seto","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"R11-20240826","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/gutjnl-2014-308989","article-title":"Serum viral duplex-linear DNA proportion increases with the progression of liver disease in patients infected with HBV","volume":"65","author":"Zhao","year":"2016","journal-title":"Gut"},{"key":"R12-20240826","doi-asserted-by":"crossref","first-page":"100449","DOI":"10.1016\/j.jhepr.2022.100449","article-title":"Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B","volume":"4","author":"van Buuren","year":"2022","journal-title":"JHEP Rep"},{"key":"R13-20240826","doi-asserted-by":"crossref","first-page":"eaan0241","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"key":"R14-20240826","doi-asserted-by":"crossref","DOI":"10.3390\/v13040581","article-title":"RNA interference therapy for chronic hepatitis B predicts the importance of addressing viral integration when developing novel cure strategies","volume":"13","author":"Wooddell","year":"2021","journal-title":"Viruses"},{"key":"R15-20240826","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061224","article-title":"Antigen load and T cell function: a challenging interaction in HBV infection","volume":"10","author":"Montali","year":"2022","journal-title":"Biomedicines"},{"key":"R16-20240826","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","article-title":"Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B","volume":"66","author":"Lebosse","year":"2017","journal-title":"J Hepatol"},{"key":"R17-20240826","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1053\/j.gastro.2012.08.046","article-title":"Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection","volume":"143","author":"Martinet","year":"2012","journal-title":"Gastroenterology"},{"key":"R18-20240826","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1172\/JCI118592","article-title":"Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection","volume":"97","author":"Rehermann","year":"1996","journal-title":"J Clin Invest"},{"key":"R19-20240826","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"R20-20240826","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhepr.2019.06.001","article-title":"HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection","volume":"1","author":"Ferrando-Martinez","year":"2019","journal-title":"JHEP Rep"},{"key":"R21-20240826","doi-asserted-by":"crossref","first-page":"S851","DOI":"10.1016\/S0168-8278(22)01999-7","article-title":"Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells","volume":"77","author":"Ganchua","year":"2022","journal-title":"J Hepatol"},{"key":"R22-20240826","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"R23-20240826","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(\u2021)","volume":"72","author":"Cornberg","year":"2020","journal-title":"J Hepatol"},{"key":"R24-20240826","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J Hepatol"},{"key":"R25-20240826","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1436","article-title":"Durability of hepatitis B surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis B","volume":"4","author":"Lok","year":"2020","journal-title":"Hepatol Commun"},{"key":"R26-20240826","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.cgh.2019.07.018","article-title":"Durability of spontaneous and treatment-related loss of hepatitis B s antigen","volume":"18","author":"Alawad","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R27-20240826","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.cgh.2019.08.033","article-title":"How do we determine whether a functional cure for HBV infection has been achieved?","volume":"18","author":"Yip","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R28-20240826","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1136\/gutjnl-2019-320015","article-title":"Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study","volume":"69","author":"Kim","year":"2020","journal-title":"Gut"},{"key":"R29-20240826","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N Engl J Med"},{"key":"R30-20240826","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0168-8278(22)00538-4","article-title":"ALT flares were linked to HBsAg reduction, seroclearance and seroconversion: interim results from a phase IIb study in chronic hepatitis B patients with 24-week treatment of subcutaneous PD-L1 Ab ASC22 (Envafolimab) plus nucleos (t)ide analogs","volume":"77","author":"Wang","year":"2022","journal-title":"J Hepatol"},{"key":"R31-20240826","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"R32-20240826","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.26041","article-title":"Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads","volume":"57","author":"Tseng","year":"2013","journal-title":"Hepatology"},{"key":"R33-20240826","doi-asserted-by":"crossref","DOI":"10.3390\/genes10050357","article-title":"The role of hepatitis B core-related antigen","volume":"10","author":"Inoue","year":"2019","journal-title":"Genes (Basel)"},{"key":"R34-20240826","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/hep.30325","article-title":"Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection","volume":"69","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"R35-20240826","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J Hepatol"},{"key":"R36-20240826","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2022.03.006","article-title":"A case of HBV-induced liver failure in the REEF-2 phase II trial: implications for finite treatment strategies in HBV \u2018cure\u2019","volume":"77","author":"Agarwal","year":"2022","journal-title":"J Hepatol"},{"key":"R37-20240826","first-page":"S736","article-title":"Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos (t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection","volume":"75","author":"Gane","year":"2021","journal-title":"J Hepatol"},{"key":"R38-20240826","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba6322","article-title":"Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection","volume":"13","author":"Nishio","year":"2021","journal-title":"Sci Transl Med"},{"key":"R39-20240826","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"R40-20240826","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"key":"R41-20240826","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","article-title":"Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatol Int"},{"key":"R42-20240826","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1572-0241.2006.00418.x","article-title":"Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype","volume":"101","author":"Flink","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R43-20240826","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.cgh.2020.04.091","article-title":"Should treatment indications for chronic hepatitis B be expanded?","volume":"19","author":"Jeng","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R44-20240826","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiab241","article-title":"Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B","volume":"224","author":"Hsu","year":"2021","journal-title":"J Infect Dis"},{"key":"R45-20240826","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"R46-20240826","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients\u2014FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"key":"R47-20240826","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"R48-20240826","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP3256","article-title":"DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B","volume":"23","author":"Papatheodoridis","year":"2018","journal-title":"Antivir Ther"},{"key":"R49-20240826","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-019-09991-y","article-title":"Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy","volume":"14","author":"Chen","year":"2020","journal-title":"Hepatol Int"},{"key":"R50-20240826","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R51-20240826","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.16968","article-title":"Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels","volume":"56","author":"Hall","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"R52-20240826","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"R53-20240826","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"R54-20240826","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","article-title":"Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels","volume":"76","author":"Sonneveld","year":"2022","journal-title":"J Hepatol"},{"key":"R55-20240826","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"R56-20240826","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","article-title":"Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2020","journal-title":"Hepatol Int"},{"key":"R57-20240826","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1002\/hep.32082","article-title":"Endpoints and new options for treatment of chronic hepatitis D","volume":"74","author":"Lok","year":"2021","journal-title":"Hepatology"},{"key":"R58-20240826","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","article-title":"Bulevirtide with or without pegIFNalpha for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies","volume":"77","author":"Lampertico","year":"2022","journal-title":"J Hepatol"},{"key":"R59-20240826","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11051349","article-title":"Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives","volume":"11","author":"Taverniti","year":"2022","journal-title":"J Clin Med"},{"key":"R60-20240826","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.32314","article-title":"Getting to HBV cure: the promising paths forward","volume":"76","author":"Fung","year":"2022","journal-title":"Hepatology"},{"key":"R61-20240826","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2468-1253(19)30190-6","article-title":"Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"S1","key":"R62-20240826","first-page":"LB5064","article-title":"Evaluation of the Vebicorvir, NRTI and AB-729 combination in virologically suppressed patients with HBeAg negative chronic hepatitis B virus infection: interim analysis from an open label phase 2 study","volume":"76","author":"George","year":"2022","journal-title":"Hepatology"},{"key":"R63-20240826","first-page":"62a","article-title":"Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"R64-20240826","first-page":"434A","article-title":"Dose response with the RNA interference (RNAi) therapy JNJ-3989 combined with nucleos(t)ide analogue (NA) treatment in expanded cohorts of patients (PTs) with chronic hepatitis B (CHB)","volume":"70","author":"Gane","year":"2019","journal-title":"Hepatology"},{"key":"R65-20240826","article-title":". HBV RNAi inhibitor RG6346 in Phase 1b-2a trial was safe, well-tolerated, and resulted in substantial and durable reductions in serum HBsAg levels","author":"Yuen","journal-title":"The Liver Meeting Digital Experience\u2122. AASLD, 2020"},{"key":"R66-20240826","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J Hepatol"},{"key":"R67-20240826","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0168-8278(20)30647-4","article-title":"Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients","volume":"73","author":"Gane","year":"2020","journal-title":"J Hepatol"},{"key":"R68-20240826","first-page":"S203","article-title":"Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression","volume":"75","author":"Yuen","year":"2021","journal-title":"J Hepatol"},{"key":"R69-20240826","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0168-8278(22)00437-8","article-title":"Efficacyand safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study","volume":"77","author":"Agarwal","year":"2022","journal-title":"J Hepatol"},{"issue":"S1","key":"R70-20240826","first-page":"LB5012","article-title":"Efficacy and safety of combination treatment with siRNA JNJ-73763989 and capsid assembly modulator JNJ-56136379 (Bersacapavir) in HBeAg negative virologically suppressed chronic hepatitis B (CHB) patients: follow-up week 48 end of study results from REEF-2","volume":"76","author":"Agarwal","year":"2022","journal-title":"Hepatology"},{"issue":"S1","key":"R71-20240826","first-page":"LB5047","article-title":"Hepatitis B viral control maintained during extended follow up of HBeAg- chronic hepatitis B (CHB) subjects who discontinued nucleos(t)ide analogue (NA) therapy after completion of AB-729 treatment, and in HBeAg+ subjects still on NA therapy","volume":"76","author":"Yuen","year":"2022","journal-title":"Hepatology"},{"issue":"S1","key":"R72-20240826","first-page":"S18","article-title":"Safety, tolerability and antiviral activity of the siRNA VIR-2218 in combination with the investigational neutralizing monoclonal antibody VIR-3434 for the treatment of chronic hepatitis B infection: preliminary results from the phase 2 MARCH trial","volume":"76","author":"Gane","year":"2022","journal-title":"Hepatology"},{"issue":"S1","key":"R73-20240826","first-page":"S19","article-title":"Preliminary 48-week safety and efficacy data of VIR-2218 alone and in combination with pegylated interferon alfa in participants with chronic HBV infection","volume":"76","author":"Yuen","year":"2022","journal-title":"Hepatology"},{"key":"R74-20240826","doi-asserted-by":"crossref","first-page":"S873","DOI":"10.1016\/S0168-8278(22)02041-4","article-title":"Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study","volume":"77","author":"You","year":"2022","journal-title":"J Hepatol"},{"key":"R75-20240826","first-page":"1390A","article-title":"Efficacy and safety of the siRNA JNJ-3989 and\/or the capsid assembly modulator (CAM) JNJ-6379 for the treatment of chronic hepatitis B virus infection (CHB): results from the phase 2b REEF-1 study","volume":"74","author":"Yuen","year":"2021","journal-title":"Hepatology"},{"key":"R76-20240826","doi-asserted-by":"crossref","first-page":"104853","DOI":"10.1016\/j.antiviral.2020.104853","article-title":"Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro","volume":"183","author":"Boulon","year":"2020","journal-title":"Antiviral Res"},{"key":"R77-20240826","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.omtn.2021.12.013","article-title":"Mechanism of action of hepatitis B virus S antigen transport-inhibiting oligonucleotide polymer, STOPS, molecules","volume":"27","author":"Kao","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"R78-20240826","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"R79-20240826","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J Hepatol"},{"key":"R80-20240826","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2018.01.030","article-title":"TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(T)Ide analogues","volume":"154","author":"Boni","year":"2018","journal-title":"Gastroenterology"},{"key":"R81-20240826","first-page":"S757","article-title":"Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis B","volume":"75","author":"Janssen","year":"2021","journal-title":"J Hepatol"},{"key":"R82-20240826","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bpg.2017.05.004","article-title":"New treatments to reach functional cure: rationale and challenges for emerging immune-based therapies","volume":"31","author":"Gehring","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R83-20240826","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis","volume":"157","author":"Boni","year":"2019","journal-title":"Gastroenterology"},{"key":"R84-20240826","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J Hepatol"},{"key":"R85-20240826","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"R86-20240826","doi-asserted-by":"crossref","first-page":"100361","DOI":"10.1016\/j.jhepr.2021.100361","article-title":"Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib\/IIa study","volume":"3","author":"Ma","year":"2021","journal-title":"JHEP Rep"},{"key":"R87-20240826","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial","volume":"16","author":"Zoulim","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"suppl 1","key":"R88-20240826","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/jvh.12791","article-title":"Recognition of core- and polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients","volume":"24","author":"Huang","year":"2017","journal-title":"J Viral Hepat"},{"key":"R89-20240826","doi-asserted-by":"crossref","first-page":"S868","DOI":"10.1016\/S0168-8278(22)02030-X","article-title":"Phase 1b\/2a study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) combined with low-dose nivolumab (LDN) in virally-suppressed patients with CHB on nucleos (t)ide analogues","volume":"77","author":"Evans","year":"2022","journal-title":"J Hepatol"},{"key":"R90-20240826","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112754","article-title":"HBV Immune-therapy: from molecular mechanisms to clinical applications","volume":"20","author":"Boni","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R91-20240826","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41575-019-0196-9","article-title":"Restoring, releasing or replacing adaptive immunity in chronic hepatitis B","volume":"16","author":"Maini","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R92-20240826","first-page":"1392A","article-title":"HBsAg loss in chronic hepatitis B patients with subcutaneous PD-L1 antibody ASC22(ENVAFOLIMAB) plus nucelos(t)ide analogs treatment: interim results from a phase IIb clinical trial","volume":"74","author":"Wang","year":"2021","journal-title":"Hepatology"},{"key":"R93-20240826","doi-asserted-by":"crossref","first-page":"e161818","DOI":"10.1172\/JCI161818","article-title":"Integrated hepatitis B virus DNA maintains surface antigen production during antivirals","volume":"132","author":"Grudda","year":"2022","journal-title":"J Clin Invest"},{"key":"R94-20240826","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jhep.2022.03.028","article-title":"The challenges of adopting immunological biomarkers in the management of chronic HBV infection","volume":"77","author":"Bertoletti","year":"2022","journal-title":"J Hepatol"},{"key":"R95-20240826","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.gastro.2020.04.019","article-title":"Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection","volume":"159","author":"Le Bert","year":"2020","journal-title":"Gastroenterology"},{"key":"R96-20240826","doi-asserted-by":"crossref","first-page":"104783","DOI":"10.1016\/j.antiviral.2020.104783","article-title":"Reasons to consider early treatment in chronic hepatitis B patients","volume":"177","author":"Koffas","year":"2020","journal-title":"Antiviral Res"},{"key":"R97-20240826","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/hepr.13723","article-title":"Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population","volume":"52","author":"Kumada","year":"2022","journal-title":"Hepatol Res"},{"key":"R98-20240826","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2020.10.022","article-title":"Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B","volume":"84","author":"Lee","year":"2021","journal-title":"Eur J Intern Med"},{"key":"R99-20240826","article-title":"The role of off-therapy viral kinetics in the timing and severity of flares in hepatitis B e antigen-negative patients","author":"Liu","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HC9.0000000000000084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T15:07:02Z","timestamp":1724684822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HC9.0000000000000084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":98,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/hc9.0000000000000084","relation":{},"ISSN":["2471-254X"],"issn-type":[{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]},"assertion":[{"value":"2022-10-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}